years of age and older weighing at least 40 kg who are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as patients who meet at least one of the following criteria:  Have a body mass index (BMI) ≥35  Have chronic kidney disease  Have diabetes  Have immunosuppressive disease  Are currently receiving immunosuppressive treatment  Are ≥65 years of age  Are ≥55 years of age AND have  cardiovascular disease, OR  hypertension, OR  chronic obstructive pulmonary disease/other chronic respiratory disease.  Are 12 – 17 years of age AND have  BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm, OR  sickle cell disease, OR  congenital or acquired heart disease, OR  neurodevelopmental disorders, for example, cerebral palsy, OR  a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR  asthma, reactive airway or other chronic respiratory disease that requires daily medication for control. 2.2 Dosage The dosage of bamlanivimab in adults and pediatric patients 12 years of age and older weighing at least 40 kg is a single intravenous (IV) infusion of 700 mg bamlanivimab administered over at least 60 minutes. Bamlanivimab should be administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset. 2.3 Dosage Adjustment in Specific Populations Pregnancy or Lactation No dosage adjustment is recommended in pregnant or lactating women [see Use in Specific Populations (11.1, 11.2)]. Pediatric Use No dosage adjustment is recommended in pediatric patients who weigh at least 40 kg. Bamlanivimab is not authorized for patients weighing less than 40 kg [see Use in Specific Populations (11.3)]. Geriatric Use No dosage adjustment is recommended in geriatric patients [see Use in Specific Populations (11.4)]. 10